Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Bharathi, Vanthana [1 ]
Bataller, Alex [2 ]
Bazinet, Alexandre [1 ]
Borthakur, Gautam [3 ]
Jabbour, Elias [1 ]
Daver, Naval [4 ]
Short, Nicholas J. [1 ]
Takahashi, Koichi [1 ]
Issa, Ghayas C. [1 ]
Dinardo, Courtney D. [1 ]
Pemmaraju, Naveen [1 ]
Jain, Nitin [1 ]
Montalban-Bravo, Guillermo [1 ]
Wierda, William G. [2 ]
Ravandi, Farhad [1 ]
Kantarjian, Hagop M. [1 ]
Kadia, Tapan M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Mol Hematol & Therapy, Houston, TX USA
[4] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-209157
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4272 / 4274
页数：3
相关论文
共 50 条
  • [21] CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia
    Talati, Chetasi
    Lancet, Jeffrey E.
    FUTURE ONCOLOGY, 2018, 14 (12) : 1147 - 1154
  • [22] CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia
    Assi, Rita
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias J.
    Gborogen, Rosilyn A.
    Chamoun, Kamal
    Wierda, William G.
    Borthakur, Gautam
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
  • [23] A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) a Study of the Polish Adult Leukemia Group (AML-1/2018): Preliminary Results of the Dose Escalation Stage
    Wierzbowska, Agnieszka
    Pluta, Agnieszka
    Stelmach, Piotr
    Sobas, Marta Anna
    Rybka, Justyna
    Wrobel, Tomasz
    Zarzycka, Ewa
    Prejzner, Witold
    Zaucha, Jan
    Szczepaniak, Andrzej
    Gil, Lidia
    Giebel, Sebastian
    BLOOD, 2022, 140 : 6165 - 6166
  • [24] Phase II Study of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality
    Borthakur, Gautam
    Kantarjian, Hagop M.
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias J.
    Kadia, Tapan
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Pemmaraju, Naveen
    Konopleva, Marina
    Ohanian, Maro
    Wierda, William G.
    Jain, Nitin
    Xiao, Lian-Chun
    Mukherjee, Paromita
    Brandt, Mark
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [25] Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Naqvi, Kiran
    Ravandi, Farhad
    Kantarjian, Hagop
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Thomas, Deborah A.
    Koller, Charles Asa
    Konopleva, Marina
    Byrd, Anna
    Kwari, Monica
    Faderl, Stefan
    BLOOD, 2010, 116 (21) : 464 - 465
  • [26] Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
    Chen, Evan C.
    Fathi, Amir T.
    Brunner, Andrew M.
    ONCOTARGETS AND THERAPY, 2018, 11 : 3425 - 3434
  • [27] CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial
    Oliai, Caspian
    Park, Sunmin
    Damon, Lloyd E.
    Jonas, Brian A.
    Jeyakumar, Deepa
    Wieduwilt, Matthew J.
    Logan, Aaron C.
    Callas, Bradley
    Hannigan, Chris A.
    Gaut, Daria L.
    Schiller, Gary J.
    LEUKEMIA & LYMPHOMA, 2024,
  • [28] Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
    Asghari, Hannah
    Lee, Dasom
    Deutsch, Yehuda E.
    Chan, Onyee
    Al Ali, Najla
    Boisclair, Stephanie
    Terrell, Constance
    Padron, Eric
    Kuykendall, Andrew T.
    List, Alan F.
    Fernandez, Hugo F.
    Lancet, Jeffrey E.
    Sallman, David A.
    Komrokji, Rami S.
    Sweet, Kendra L.
    Talati, Chetasi
    BLOOD, 2019, 134
  • [29] CPX-351 ASSOCIATED RASH IN PEDIATRIC PATIENTS WITH ACUTE MYELOID LEUKEMIA: A CASE SERIES
    Weisnicht, Allison
    Chan, Audrey
    Stevens, Alexandra
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S56 - S56
  • [30] Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia
    Asghari, Hannah
    Lancet, Jeffrey
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1305 - 1312
12345